South African Scientists Decode MUC1’s T13 Cancer Switch, Opening Path to Vaccines
Updated
Updated · The Conversation · Jun 18
South African Scientists Decode MUC1’s T13 Cancer Switch, Opening Path to Vaccines
3 articles · Updated · The Conversation · Jun 18
Summary
Nature Communications published a South African-led study showing cancer rewires the MUC1 protein’s sugar coating, helping tumours evade immune detection and drive growth.
The team recreated that shift in a test-tube model and found enzymes that start sugar chains move from the Golgi to the endoplasmic reticulum, where they generate tumour-linked Tn antigens without normal cellular restraints.
Quantum-chemistry simulations then pinpointed the T13 site on MUC1 as a preferred target, explaining the sharp rise of the malignant sTn antigen in tumours.
Because MUC1 appears across many cancers and is ranked by the U.S. National Cancer Institute as a leading accessible target, the findings could guide biomarkers, vaccines and drugs that strip away cancer’s sugar shield.
Researchers are now building systems-biology models and comparing breast-cancer subtypes to link these sugar changes to immune-cell signalling and precision treatments.
Is a faulty sugar coating cancer's universal trick, and could a single key unlock treatments for many different types?
Cancer uses a sugar 'invisibility cloak' to hide. Can a new generation of drugs finally strip it away for good?
Cancer’s Hidden Shield: How the T13-MUC1-sTn Axis Drives Immune Evasion and Opens New Paths for Precision Therapy
Overview
A major scientific breakthrough published in May 2024 revealed how cancer cells evade the immune system by focusing on the MUC1 protein. Researchers discovered that the enzyme GALNT13 (T13) is highly active in aggressive cancers, acting as a molecular switch that causes abnormal sugar modifications on MUC1. This leads to the buildup of the cancer-associated sTn antigen, which forms a dense protective layer—called a glycocalyx—around cancer cells. This shield helps tumors hide from immune attack, offering new insights and potential targets for more precise cancer therapies.